Skip to main content
Annolyse

Company archive

Rua Bioscience (RUA) briefings

Read that company's published results in release order, newest first.

Rua Bioscience (RUA)FY26Released 28 August 2026

Revenue rose 93.5% while borrowings climbed 55.9%

Revenue reached $2.9m and cash rose to $0.534m, but operating cash outflow widened to $3.0m.

Published 29 August 2026

Read briefing
Rua Bioscience (RUA)HY26Released 27 February 2026

Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled

A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.

Published 22 May 2026

Read briefing
Rua Bioscience (RUA)FY25Released 1 September 2025

RUA revenue rose 490.6% but the business remains deeply cash-negative

Strong commercial momentum cut the loss before tax by 74.8%, yet cash fell to NZD 0.2m and operating outflows persist, making runway the central

Published 19 May 2026

Read briefing
Rua Bioscience (RUA)HY24Released 29 February 2024

Goodwill impairment of $8.3m drives HY24 loss of $10.9m

Management writes off a prior acquisition that failed to deliver, leaving a $1.0m cash buffer and ongoing operating burn.

Published 28 April 2026

Read briefing
Rua Bioscience (RUA)FY23Released 29 August 2023

Customer revenue $0.4m as cash burn $5.9m leaves $2.5m on hand

Headline revenue of $6.5m is dominated by fair value gains on contingent consideration; commercial revenue remains immaterial against ongoing burn.

Published 23 April 2026

Read briefing
Rua Bioscience (RUA)HY23Released 28 February 2023

Reported $0.7m profit masks unchanged $3.7m cash burn against $1.7m balance

Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.

Published 23 April 2026

Read briefing
Rua Bioscience (RUA)FY22Released 29 August 2022

Cash falls to $1.9m as operating burn widens to $6.8m

First product sales arrived but losses widened materially, leaving only months of cash at the current operating burn rate.

Published 22 April 2026

Read briefing
Rua Bioscience (RUA)HY22Released 25 February 2022

Operating cash burn nearly doubled to $3.7m before first revenue

Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.

Published 22 April 2026

Read briefing

Get reporting-season briefings

Get full NZX result briefings by email as new coverage is published.